Favorable Response in Statin-Naive Paraneoplastic Anti-HMGCR Antibody-Associated Myopathy to Single Dose of Rituximab and Persistent Remission With Management of Underlying Lung Cancer.
We report a case of a statin-naive paraneoplastic anti-HMGCR myopathy, who unlike other reported cases, responded to a single dose of 1000 mg of intravenous rituximab and subsequent chemoradiation therapy for an underlying lung cancer, despite failing to completely respond to prior high-dose oral prednisone and methotrexate.
PMID: 31453850 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Waheed W, Jones C, Gentchos G, DeWitt J, Tandan R Tags: J Clin Neuromuscul Dis Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Cholesterol | Immunotherapy | Lung Cancer | Methotrexate | Neurology | Oral Cancer | Paraneoplastic Syndrome | Prednisone | Rituxan | Statin Therapy | Study